SENS Senseonics Holdings

Senseonics Holdings, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for August 6, 2025 at 4:30 P.M. Eastern Time

Senseonics Holdings, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for August 6, 2025 at 4:30 P.M. Eastern Time

GERMANTOWN, Md., July 16, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its second quarter 2025 financial results after market close on Wednesday, August 6, 2025.

Management will hold a conference call to review the Company’s second quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. To listen to the conference call, please dial 1-800-225-9448 (US/Canada) or 1-203-518-9708 (International), passcode SENSQ2, approximately ten to five minutes prior to start time.

About Senseonics

Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

Senseonics Investor Contact

Jeremy Feffer

LifeSci Advisors





EN
16/07/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Senseonics Holdings

 PRESS RELEASE

Senseonics Holdings, Inc. Schedules Second Quarter 2025 Earnings Relea...

Senseonics Holdings, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for August 6, 2025 at 4:30 P.M. Eastern Time GERMANTOWN, Md., July 16, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its second quarter 2025 financial results after market close on Wednesday, August 6, 2025. Management will hold a conference call to review the C...

 PRESS RELEASE

Senseonics Holdings, Inc. to Host In-Person and Virtual Analyst Event ...

Senseonics Holdings, Inc. to Host In-Person and Virtual Analyst Event at ADA 2025: Eversense® 365 Continuous Glucose Monitoring System for People with Diabetes GERMANTOWN, Md., June 04, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced it will host an in-person and virtual analyst event in conjunction with the American Diabetes Association 85th Scientific Sessions (ADA 2025), on Sat...

Research Team ACF
  • Research Team ACF

KDST + NLSP Combined Core Investment Case 29052025

We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod...

 PRESS RELEASE

Senseonics Holdings, Inc. Announces Closing of Public Offering, Includ...

Senseonics Holdings, Inc. Announces Closing of Public Offering, Including Exercise in Full of the Underwriters’ Option to Purchase Additional Shares, and Closing of Private Placement Public offering results in gross proceeds of $57.5 millionPrivate placement results in gross proceeds of approximately $20.3 million GERMANTOWN, Md., May 21, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today ann...

 PRESS RELEASE

Senseonics Announces Pricing of $50 Million Public Offering of Common ...

Senseonics Announces Pricing of $50 Million Public Offering of Common Stock and Concurrent Private Placement GERMANTOWN, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the pricing of an underwritten public offering of 100,000,000 shares of common stock at a price to the public of $0.50 per share of common stock. The gross proceeds to Senseonics from the offering, bef...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch